Ontario court approves AstraZeneca/Fusion acquisition plan (NASDAQ:AZN)

Fusion Pharmaceuticals (NASDAQ:FUSN) said the Ontario Superior Court of Justice has approved its statutory plan of arrangement to be acquired by a wholly owned subsidiary of AstraZeneca (NASDAQ:AZN).

Under the arrangement, Fusion shareholders will receive $21 per share upfront plus a deferred payment of $3 per share in the form of a contingency right value when a certain regulatory milestone is achieved.